Bayer Warns Planned German Price Curbs May Restrict Drug Access

  • Germany looking at revenue ceiling for drugs in first year
  • Government also considering extending cap on older drugs

Bayer AG, Roche Holding AG and other drugmakers are warning that a German government proposal to tighten price controls on prescription drugs could end up restricting access to new medicines in Europe’s biggest health-care market.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.